During the last session, NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s traded shares were 0.74 million, with the beta value of the company hitting -0.06. At the end of the trading day, the stock’s price was $19.91, reflecting an intraday gain of 2.63% or $0.51. The 52-week high for the NAMS share is $27.29, that puts it down -37.07 from that peak though still a striking 23.71% gain since the share price plummeted to a 52-week low of $15.19. The company’s market capitalization is $2.13B, and the average intraday trading volume over the past 10 days was 0.57 million shares, and the average trade volume was 912.34K shares over the past three months.
NewAmsterdam Pharma Company NV (NAMS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NAMS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.47.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
NewAmsterdam Pharma Company NV (NAMS) registered a 2.63% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.63% in intraday trading to $19.91, hitting a weekly high. The stock’s 5-day price performance is -1.39%, and it has moved by -17.04% in 30 days. Based on these gigs, the overall price performance for the year is -0.45%. The short interest in NewAmsterdam Pharma Company NV (NASDAQ:NAMS) is 2.8 million shares and it means that shorts have 3.98 day(s) to cover.
The consensus price target of analysts on Wall Street is $41, which implies an increase of 51.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $36 and $48 respectively. As a result, NAMS is trading at a discount of -141.08% off the target high and -80.81% off the low.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
In the rating firms’ projections, revenue will increase 138.76% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.67M as predicted by 10 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 2.53M by the end of current fiscal year.
While earnings are projected to return 5.52% in 2025, the next five years will return 7.70% per annum.
NAMS Dividends
NewAmsterdam Pharma Company NV is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
NewAmsterdam Pharma Company NV insiders own 0.41% of total outstanding shares while institutional holders control 94.94%, with the float percentage being 95.33%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the largest shareholder of the company, while 156.0 institutions own stock in it. As of 2024-06-30, the company held over 12.23 million shares (or 12.9097% of all shares), a total value of $234.88 million in shares.
The next largest institutional holding, with 11.83 million shares, is of FCPM III SERVICES B.V.’s that is approximately 12.4921% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $227.28 million.
Also, the Mutual Funds coming in first place with the largest holdings of NewAmsterdam Pharma Company NV (NAMS) shares are AB Cap Fd.-AB Small Cap Growth Port and PGIM Jennison Health Sciences Fd . Data provided on Dec 31, 2024 indicates that AB Cap Fd.-AB Small Cap Growth Port owns about 573.26 shares. This amounts to just over 0.62 percent of the company’s overall shares, with a $11.41 million market value. The same data shows that the other fund manager holds slightly less at 489.12, or about 0.53% of the stock, which is worth about $9.74 million.
